<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730951</url>
  </required_header>
  <id_info>
    <org_study_id>107460</org_study_id>
    <nct_id>NCT00730951</nct_id>
  </id_info>
  <brief_title>The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation</brief_title>
  <official_title>The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the use of herbals is increasing considerably, their efficacy and safety in the humans&#xD;
      remains largely unknown. This surge in demand prompts a call for its evaluation. Preliminary&#xD;
      data demonstrates that KRG can affect vascular function and our research group has previously&#xD;
      shown that Korean Red Ginseng (KRG) can lower blood pressure (BP) in hypertensive&#xD;
      individuals. However, it is unknown which dose is the most effective in producing a desired&#xD;
      effect. To address this issue, we will test escalating doses of a single Korean red ginseng&#xD;
      batch of 0.5g, 1g 3g and 6g on BP in patients with hypertension to determine the most&#xD;
      efficacious dose. The most promising dose will be extracted and will advance to next level to&#xD;
      be tested again on BP control. The findings of the study may result in better ginseng&#xD;
      standardization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals will arrive at the Risk Factor Modification Centre, St. Michael's Hospital&#xD;
      between the hours of 8:00 and 10:00am after a 10 to 12-hour fast on seven separate mornings.&#xD;
      They will not have consumed any antihypertensive medications on the study mornings. Each&#xD;
      visit will be separated by a minimum of a week. Since the half-life of ginsenosides in humans&#xD;
      is less than 24-hours, to allow for a washout of approximately seven half-lives.&#xD;
&#xD;
      In each of the four studies, when individuals arrive at our clinic on a test day they will&#xD;
      first have their weight measured and subsequently rest in the seated position. They will then&#xD;
      have a catheter inserted into a forearm vein, which will be kept patent by saline. From this&#xD;
      device, a registered intravenous nurse will obtain a series of 7ml blood samples. Blood will&#xD;
      be taken at 30-min intervals. Subsequently, individuals will fill out forms detailing their&#xD;
      pharmacological regimen for the previous 24-hours and their diet (dinner) and activity&#xD;
      (sleep, urination, morning routine) regimen for the previous 12-hours. As well, they will&#xD;
      detail any adverse events that they experienced since their previous visit. Individuals will&#xD;
      then have their office BP measured with a mercury sphygmomanometer until three consecutive&#xD;
      measurements of both SBP and DBP &lt;5 mmHg different are obtained. At this point, BP should be&#xD;
      steady and subjects will be fitted with an ABPM. Measurements will be taken every 5-min for&#xD;
      30-min, for a total of seven measurements. After the seventh measurement (time 0-min),&#xD;
      measurements will be taken automatically every 10-min for 180-min. At time 0-min, treatment&#xD;
      or placebo capsules will be consumed. At time 60-min a 360-calorie EnsureÂ® breakfast will be&#xD;
      consumed within 5-min. Blood samples will be drawn at 30-min intervals, starting at time&#xD;
      0-min. For 24-hours after the ingestion of treatment, a record of any side effects will be&#xD;
      detailed by the participants and then provided to us.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure will be measured with an Ambulatory Blood Pressure Monitor</measure>
    <time_frame>every 5 min for first 30 min, then every 10 minutes for 180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood samples will be drawn and tested for Nitric Oxide levels.</measure>
    <time_frame>every 30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6g Korean Red Ginseng (12 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6g Corn Starch Control (12 capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Korean Red Ginseng</intervention_name>
    <description>500mg Capsulated Ground Dried Korean Red Ginseng Root</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn Starch</intervention_name>
    <description>500mg Capsulated Corn Starch</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Essential Hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary Hypertension&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Chronic Kidney Disease&#xD;
&#xD;
          -  Liver Disease&#xD;
&#xD;
          -  Unstable Angina&#xD;
&#xD;
          -  Coronary / Cerebrovascular event in the previous 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Vuksan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Nutritian and Risk Factor Modification Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Nutrition and Risk Factor Modification Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

